

Equality Impact Assessment Tool

TP 08 - Policy and procedure for: Supply of medicines under Patient Group Directions

		Yes/No	Comments
1.	Does the document/guidance affect one group less or more favourably than another on the basis of:		
	• Race	NO	<p>This policy sets out how under the current drugs legislation a patient group direction (PGD) for a drug, or group of drugs, will be drawn up by the LAS</p> <p>The policy further details how the education and training on PGDs is to be carried out, and who is allowed to use PGD drugs</p> <p>This version of the policy is essentially a revision of an existing policy which it brings up to date to take account of the change in format of the manner in which PGDs are physically produced. IE One sign off sheet for a group of PGDs, rather than individual sign off sheets per drug.</p>
	• Ethnic origins (including gypsies and travellers)	NO	
	• Nationality	NO	
	• Gender	NO	
	• Culture	NO	
	• Religion or belief	NO	
	• Sexual orientation including lesbian, gay and bisexual people	NO	
	• Age	NO	
	• Disability - learning disabilities, physical disability, sensory impairment and mental health problems	NO	
2.	Is there any evidence that some groups are affected differently?	NO	
3.	If you have identified potential discrimination, are there any exceptions valid, legal and/or justifiable?	N/A	
4.	Is the impact of the document/guidance likely to be negative?	NO	This EQIA was undertaken by David Whitmore, Senior Clinical adviser to the Medical Director.
5.	If so, can the impact be avoided?	N/A	
6.	What alternative is there to achieving the document/guidance without the impact?	N/A	17 th February 2010
7.	Can we reduce the impact by taking different action?	N/A	